Breast cancer incidence and menopausal hormone therapy in Norway from 2004 to 2009: a register-based cohort study

English version České info

Abstract:
In Norway, the breast cancer incidence increased by 50% in the 1990s, during a period with initiation of mammography screening as well as a fourfold increase in use of menopausal hormone therapy (HT). After 2002, the HT use has dropped substantially; however, the breast cancer incidence has declined only marginally. How much mammography screening contributed to the breast cancer incidence increase in the 1990s compared with HT use and specifically different types of HT use, has thus been discussed. Whether HT affects the incidence of subtypes of breast cancer differently has also been questioned. We have linked individual data from several national registries from 2004 to 2009 on 449,717 women aged 50–65 years. 4597 cases of invasive cancer and 681 cases of ductal carcinoma in situ (DCIS) were included in the analysis. We used Cox regression to estimate hazard ratio (HR) as a measure of the relative risk of breast cancer associated with use of HT. The HRs associated with prescriptions of HT for more than 1 year were 2.06 (1.90–2.24) for estrogen and progesterone combinations, 1.03 (0.85–1.25) for systemic estrogens, and 1.23 (1.01–1.51) for tibolone. Invasive lobular carcinoma was more strongly associated with use of estrogen and progesterone combinations, HR = 3.10 (2.51–3.81), than nonlobular carcinoma, HR = 1.94 (1.78–2.12). The corresponding value for DCIS was 1.61 (1.28–2.02). We estimated the population attributable fraction to 8.2%, corresponding to 90 breast cancer cases in 2006 indicating that HT use still caused a major number of breast cancer cases.

Keywords:
Breast cancer; hormone therapy; mammography and invasive lobular carcinoma

Autoři: Pål Suhrke ^1,2; Per-Henrik Zahl ³
Působiště autorů: Department of Pathology, Oslo University Hospital, Oslo, Norway ¹; Department of Pathology, Vestfold Hospital Trust, Tønsberg, Norway ²; Norwegian Institute of Public Health, Oslo, Norway ³
Vyšlo v časopise: Cancer Medicine 2015; 4(8)
Kategorie: Original Research
prolekare.web.journal.doi_sk: https://doi.org/10.1002/cam4.474

© 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
© 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Souhrn

Keywords:
Breast cancer; hormone therapy; mammography and invasive lobular carcinoma

Zdroje

1. Jørgensen, K. J., and P. C. Gøtzsche. 2009. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. BMJ 339:b2587.

2. Hofvind, S., B. Moller, S. Thoresen, and G. Ursin. 2006. Use of hormone therapy and risk of breast cancer detected at screening and between mammographic screens. Int. J. Cancer 118:3112–3117.

3. Bakken, K., E. Alsaker, A. E. Eggen, and E. Lund. 2004. Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian Women and Cancer study. Int. J. Cancer 112:130–134.

4. 1997. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 350:1047–1059.

5. Ross, R. K., A. Paganini-Hill, P. C. Wan, and M. C. Pike. 2000. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J. Natl. Cancer Inst. 92:328–332.

6. Magnusson, C., J. A. Baron, N. Correia, R. Bergström, H. O. Adami, and I. Persson. 1999. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int. J. Cancer 81:339–344.

7. Schairer, C., J. Lubin, R. Troisi, S. Sturgeon, L. Brinton, and R. Hoover. 2000. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283:485–491.

8. Rossouw, J. E., G. L. Anderson, R. L. Prentice, A. Z. LaCroix, C. Kooperberg, M. L. Stefanick, et al. 2002. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288:321–333.

9. Beral, V. 2003. Million women study collaborators. Breast cancer and hormone-replacement therapy in the million women study. Lancet 362:419–427.

10. Suhrke, P., J. Mæhlen, and P. H. Zahl. 2012. Hormone therapy use and breast cancer incidence by histological subtypes in Sweden and Norway. Breast J. 18:549–556.

11. Kumle, M. 2008. Declining breast cancer incidence and decreased HRT use. Lancet 372:608–610.

12. Hofvind, S., S. Sakshaug, G. Ursin, and S. Graff-Iversen. 2012. Breast cancer incidence trends in Norway–explained by hormone therapy or mammographic screening? Int. J. Cancer 130:2930–2938.

13. Zahl, P. H., B. H. Strand, and J. Maehlen. 2004. Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study. BMJ 328:921–924.

14. Hofvind, S., B. Geller, P. M. Vacek, S. Thoresen, and P. Skaane. 2007. Using the European guidelines to evaluate the Norwegian Breast Cancer Screening Program. Eur. J. Epidemiol. 22:447–455.

15. Weedon-Fekjær, H., K. Bakken, L. J. Vatten, and S. Tretli. 2012. Understanding recent trends in incidence of invasive breast cancer in Norway: age-period-cohort analysis based on registry data on mammography screening and hormone treatment use. BMJ 344:e299. doi: 10.1136/bmj.e299

16. Chen, C. L., N. S. Weiss, P. Newcomb, W. Barlow, and E. White. 2002. Hormone replacement therapy in relation to breast cancer. JAMA 287:734–741.

17. Daling, J. R., K. E. Malone, D. R. Doody, L. F. Voigt, L. Bernstein, R. J. Coates, et al. 2002. Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer 95:2455–2464.

18. Newcomer, L. M., P. A. Newcomb, J. D. Potter, Y. Yasui, A. Trentham-Dietz, B. E. Storer, et al. 2003. Postmenopausal hormone therapy and risk of breast cancer by histologic type (United States). Cancer Causes Control 14:225–233.

19. Li, C. I., J. R. Daling, K. L. Haugen, M. T. Tang, P. L. Porter, and K. E. Malone. 2014. Use of menopausal hormone therapy and risk of ductal and lobular breast cancer among women 55–74 years of age. Breast Cancer Res. Treat. 145:481–489.

20. Luo, J., B. B. Cochrane, J. Wactawski-Wende, J. R. Hunt, J. K. Ockene, and K. L. Margolis. 2013. Effects of menopausal hormone therapy on ductal carcinoma in situ of the breast. Breast Cancer Res. Treat. 137:915–925.

21. Heiss, G., R. Wallace, G. L. Anderson, A. Aragaki, S. A. Beresford, R. Brzyski, et al. 2008. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin JAMA 299:1036–1045.